Smoking and schizophrenia

Joseph P. McEvoy, John Lindgren

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Patients with schizophrenia smoke at a higher prevalence rate (80%) than the general population (30%). Those patients with schizophrenia who smoke have an earlier age of onset and may have more refractory psychopathology. Smoking improves sensory gating, sustained attention, and cognitive performance in patients with schizophrenia. Conventional antipsychotic drugs initially increase smoking. Switching to the atypical antipsychotic, clozapine, decreases smoking. Smoking decreases the bioavailability of many antipsychotic drugs.

Original languageEnglish (US)
Pages (from-to)263-266
Number of pages4
JournalDrug Development Research
Volume38
Issue number3-4
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Keywords

  • Antipsychotic drugs
  • Nicotine
  • Schizophrenia
  • Smoking

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'Smoking and schizophrenia'. Together they form a unique fingerprint.

  • Cite this